Physician profile
John T Brunts
NPI 1578555066
$2,940.50
in general payments reported to CMS, 2019-2025
26 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2021: $185 · 2022: $133 · 2023: $549 · 2024: $724 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $633.12 | 2019-2025 | Amplatzer Talisman, Confirm Rx |
| Siemens Medical Solutions USA, INC. | $405.96 | 2023-2025 | Acuson Origin Diagnostic Ultrasound System |
| E.R. Squibb & Sons, L.L.C. | $298.64 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $241.65 | 2019-2025 | |
| Boston Scientific Corporation | $237.80 | 2023-2024 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $157.08 | 2023-2025 | Farxiga, Wainua |
| Amgen INC. | $119.74 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.12 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $103.25 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $94.22 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $73.70 | 2023-2025 | Verquvo |
| Esperion Therapeutics, INC. | $54.02 | 2025 | Nexletol |
| Medtronic, INC. | $53.15 | 2024 | Micra, Linq II |
| Lantheus Medical Imaging, INC. | $51.03 | 2019-2025 | |
| Heartflow, INC. | $43.15 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $39.11 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.84 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $37.35 | 2019 | |
| Covidien LP | $23.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.01 | 2024 | Xarelto |
| Cvrx, INC. | $18.67 | 2025 | Barostim Neo System |
| Pacira Pharmaceuticals Incorporated | $18.41 | 2024 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $16.51 | 2024 | |
| Solventum Corporation | $16.17 | 2025 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Cordis US Corp. | $15.72 | 2025 | Mynx Control Venous |
| Sanofi-Aventis U.S. LLC | $14.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brunts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.